MedTrace Logo

Intra-operative Radiotherapy For Breast Cancer Women After NSM

NCT02389686 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2015-03-17

No results posted yet for this study

Summary

The role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC).INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative radiotherapy (IORT) device to date. This study aims to assess the value of the INTRABEAM system for breast cancer.

Conditions

  • Breast Neoplasms

Interventions

DEVICE

INTRABEAM (Carl Zeiss, Oberkochen, Germany)

Boost with 16 Gy during NSM for nipple-areola complex (NAC)

Sponsors & Collaborators

  • Liao Ning

    lead OTHER

Principal Investigators

  • Liao Ning, MD,PhD · Guangdong Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2019-10-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02389686 on ClinicalTrials.gov